| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology | ||
Phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology | ||
Phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology |
Recent Updates
Recently added Catalysts
Molecular Partners AG$4.02
0 (0%)
C 47Pipeline Score Fair Value Biotech · Clinical
Market Cap
161.96 M
EPS
-1.93
P/E Ratio
-
Value Trade
57.28 K
8.57 %
Week
-3.69 %
1 Month
-11.01 %
3 Month
1.83 %
6 Month
-79.1 %
5 Year
-79.1 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
2.35 K
52 Week Range
3.41 - 5.36
% held by Insiders
0.28 %
% held by Institutions
9.57 %
Enterprise Value
68.10 M
Total Shares
37.51 M
Short %
0.03 %
Float Shares
37.41 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Molecular Partners AG
361Total events
8Upcoming
71Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 8
2025-H2
T2Other Regulator Milestone
Update on MP0712 imaging under Section 21 in South Africa expected H2 2025
Event history 353
Jun 2, 2026
●Poster PresentationMP0712Presentation
Poster presentation at SNMMI 2026
small cell lung cancer and other DLL3-expressing solid tumorssource ↗
May 30, 2026
●Poster PresentationMP0712Presentation
Trial-in-progress poster presentation at ASCO 2026
small cell lung cancer and other DLL3-expressing solid tumorssource ↗
May 30, 2026
▲First Patient DosedMP0712Trial
First patient dosed in Phase 1/2a study of MP0712
small cell lung cancer and other neuroendocrine cancerssource ↗
May 29, 2026
◆Oral PresentationMP0712Presentation
Oral presentation at Antibody & Engineering Therapeutics on MP0712
small cell lung cancer (SCLC)source ↗
May 27, 2026
◆Oral PresentationPresentation
Fireside chat at TD Cowen's 7th Annual Oncology Innovation Summit
May 13, 2026
◆Oral PresentationMP0712Presentation
Oral presentation at 22nd Annual PEGS Boston on MP0712
small cell lung cancer (SCLC)source ↗
May 12, 2026
▲Trial InitiationMP0712Trial
Phase 1/2a study of MP0712 started
small cell lung cancer and other neuroendocrine cancerssource ↗
May 12, 2026
▲Trial InitiationMP0317 + Gemcitabine + Cisplatine + DurvalumabTrial
Investigator-initiated Phase 2 study of MP0317 started
advanced cholangiocarcinomasource ↗
May 12, 2026
●Enrollment UpdateMP0712Trial
Four clinical sites open for MP0712 trial, nine expected by end of 2026
small cell lung cancer and other neuroendocrine cancerssource ↗
May 12, 2026
●Enrollment UpdateMP0317 + Gemcitabine + Cisplatine + DurvalumabTrial
Eight sites activated for MP0317 Phase 2 study
advanced cholangiocarcinomasource ↗
May 12, 2026
▲Enrollment CompleteMP0533 monotherapy, Part 1Trial
Dose escalation part fully recruited (10 cohorts)
relapsed/refractory AML and MDS/AMLsource ↗
Drug Pipeline Intelligence
C47
Pipeline Score $460M
Pipeline ValueFair Value
Valuation Signal7
Drugs Scored2.8x
rNPV / MCap Top 70%
Micro Cap (rank 274 of 911)
Percentile RankMolecular Partners AG carries a moderate pipeline score (47/100), with $3.5B risk-adjusted pipeline value, led by MP0420 in COVID-19 (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MP0420 Small molecule | COVID-19 | Phase 3 | NCT05780463 | 56% | $1.6B | COMPLETED | 485 | - | - | Jun 8, 2023 | - | Feb 5, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
MP0317 | advanced solid tumors | Phase 1 | 2026-05-01 | total patients: 46; unconfirmed partial response: 1; stable disease: 14 Read More | Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling Read More | |
MP0317 | advanced solid tumors | Phase 1 | 2026-05-01 | total patients: 46; unconfirmed partial response: 1; stable disease: 14 Read More | Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling Read More | |
MP0317 | advanced solid tumors | Phase 1 | 2026-05-01 | total patients: 46; unconfirmed partial response: 1; stable disease: 14 Read More | Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MOLN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MOLN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MOLN▼ -6%on this news
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
Molecular Partners announced presentations at ASCO and SNMMI 2026 regarding its Phase 1/2a study of MP0712, a targeted alpha radiotherapy candidate for small cell lung cancer. The study is currently dosing patients and aims to assess safety and determine a recommended Phase 2 dose. Initial clinical data is anticipated later in 2026.
Read more →MOLNMolecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
Molecular Partners AG, a clinical-stage biotech firm specializing in DARPin therapeutics, will present at TD Cowen's 7th Annual Oncology Innovation Summit on May 27, 2026. The management team will participate in a fireside chat at the event, which will be webcasted for broader access. This participation highlights the company's efforts to showcase their innovative approaches in overcoming treatment challenges in cancer.
Read more →MOLNMolecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
Molecular Partners AG reported strong financial results and clinical advancements for Q1 2026, highlighting the initiation of clinical studies for its lead programs, MP0712 and MP0317. The company emphasized a solid financial runway with 79 million CHF in cash and the successful opening of multiple trial sites. Initial clinical data for MP0712, targeting small cell lung cancer, is expected within the year. Additionally, new approaches in isotopes for the Radio-DARPin therapy aim to enhance treatment strategies across various cancers.
Read more →MOLNMolecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
Molecular Partners AG announced its participation in several upcoming scientific conferences to present its lead Radio-DARPin candidate MP0712. The presentations will focus on the drug's molecular characteristics and its development for targeted anti-DLL3 radiotherapy in small cell lung cancer. These events are significant for showcasing advancements in their therapeutic approach.
Read more →MOLNMolecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
Molecular Partners has published positive Phase 1 data for MP0317, demonstrating its ability to activate CD40 specifically within the tumor microenvironment, which could lead to improved efficacy and reduced side effects compared to traditional therapies. The study showed a favorable safety profile and evidence of tumor microenvironment remodeling. A Phase 2 trial for cholangiocarcinoma is currently underway.
Read more →MOLNMolecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
Molecular Partners AG has presented new preclinical data at the AACR Annual Meeting 2026, showcasing the Switch-DARPin T cell engager MP0632 aimed at treating MSLN and EpCAM expressing tumors. Additionally, the company introduced MP0712, a Radio-DARPin candidate currently in a Phase 1/2a trial for small cell lung cancer. The data highlights MP0632's potential for selective tumor cell targeting with minimal impact on non-targeted cells, and a novel computational workflow aiding in the discovery of tumor-associated antigens. The findings suggest significant advances in cancer immunotherapy and targeted therapies.
Read more →MOLNMolecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
Molecular Partners AG announced the election of Clare Fisher to its Board of Directors during the Annual General Meeting. Shareholders approved all proposals put forth by the Board, showing significant backing for its direction. Fisher brings over two decades of experience in the pharmaceutical industry, particularly in corporate development and strategy. Additionally, the AGM confirmed the financial results for 2025 and re-elected current board members while providing discharge for the previous financial year. This move signals a commitment to strong governance and strategic growth.
Read more →MOLNMolecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
Molecular Partners has announced the invitation to its Annual General Meeting scheduled for April 14, 2026, where Clare Fisher is nominated for election to the Board of Directors. Fisher brings over two decades of experience in biotech and corporate development. Current board member Steven H. Holtzman will not seek re-election after 12 years of service.
Read more →MOLNMolecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes
Molecular Partners AG presented new preclinical data on Radio-DARPins that demonstrate their suitability for multiple isotopes at the 3rd Global Radiopharmaceuticals Development Summit. The data indicate comparable biodistribution profiles for two candidates labeled with Lutetium-177 and Lead-203, suggesting potential efficacy in tumor targeting. The company's innovative approach allows for the selection of therapeutic isotopes late in the drug development process, which could streamline treatments tailored to patient needs. Moreover, the partnership with Eckert & Ziegler is expected to bolster the development of these novel therapeutics.
Read more →MOLNMolecular Partners to Hold Three Poster Presentations at AACR 2026
Molecular Partners AG, a clinical-stage biotech company, announced that it will hold three poster presentations at the AACR 2026 Annual Meeting in San Diego. The presentations will cover topics including an innovative T cell engager designed for improved safety in cancer therapy and a study on the molecular characteristics of a new Radio-DARPin candidate targeting small cell lung cancer. The company's focus on advancing DARPin therapeutics highlights its ongoing commitment to develop novel cancer treatment strategies.
Read more →MOLNMolecular Partners Reports Highlights and Financial Results for Full Year 2025
Molecular Partners AG announced significant advancements in its drug development pipeline and financial standing for the full year 2025. The company has initiated a Phase 1/2a clinical trial for its Radio-DARPin candidate MP0712, targeting DLL3 for small cell lung cancer. Financially, they report a strong position with CHF 93.1 million in cash, securing operations until 2028. Additionally, developments in other Radio-DARPin candidates and strategic partnerships were also highlighted, setting the stage for future growth.
Read more →MOLNMolecular Diagnostics Market Outlook: Set to Grow at 10%+ CAGR Through 2031 as Precision Medicine and Genetic Testing Advance, Says Mordor Intelligence
The molecular diagnostics market is set to grow significantly, with projections reaching $33.51 billion by 2031 at a CAGR of 10.43%. This growth is driven by a rise in the prevalence of infectious and chronic diseases, coupled with advancements in genomic and molecular testing technologies. As healthcare systems increasingly prioritize precision medicine, the demand for molecular diagnostics continues to strengthen. Key regions contributing to this market growth include North America, Europe, and the Asia-Pacific, supported by innovations and investments in healthcare infrastructure.
Read more →MOLNMolecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics
Molecular Partners has signed a development agreement with Eckert & Ziegler to advance Radio-DARPin therapeutics, which utilize alpha-emitting isotopes for targeted cancer treatment. This partnership aims to enhance the development and manufacturing processes for these innovative therapies. The agreement will leverage Eckert & Ziegler's expertise and facilities, including a dedicated Alpha Laboratory in Berlin.
Read more →MOLNMolecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
Molecular Partners AG has announced its participation in upcoming investor conferences, including the TD Cowen 46th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference. The company's CEO will take part in fireside chats during these events. Additionally, Molecular Partners will release its full-year 2025 financial report on March 12, 2026.
Read more →MOLN▲ +7.5%on this news
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
Molecular Partners presented promising imaging and dosimetry data for MP0712, a DLL3-targeted radiotherapy, at the Theranostics World Congress 2026. The data, derived from five patients, indicate favorable tumor uptake and minimal healthy tissue accumulation. This supports the ongoing Phase 1/2a study aimed at assessing the safety and efficacy of MP0712 in treating small cell lung cancer and other neuroendocrine cancers.
Read more →MOLNMolecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
Molecular Partners AG has announced advancements in its clinical development pipeline during the 44th Annual J.P. Morgan Healthcare Conference. The company has initiated a Phase 1/2a study for MP0712, with first patient dosing anticipated in Q1 2026. Additionally, details on MP0317 and MP0533 were shared, with ongoing trials exploring their efficacy in various cancers. The company also mentioned its strong financial position, projected to support operations until 2028.
Read more →MOLNMolecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
Molecular Partners AG will present its latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Patrick Amstutz is scheduled to speak on January 15, highlighting the company's focus on DARPin therapeutics and ongoing clinical programs. The presentation will be accessible via a webcast on the company's website.
Read more →MOLNMolecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
Molecular Partners has established a Scientific Advisory Board chaired by Prof. Ken Herrmann to advance its targeted radiotherapeutics. The board will focus on the development of Radio-DARPin candidates, including MP0712, which shows early promise in clinical trials. The collaboration aims to enhance strategic clinical decisions and improve treatment options for cancer patients.
Read more →MOLN▼ -7%on this newsshared move
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
Molecular Partners has presented updated data from a Phase 1/2a trial of its T-cell engager MP0533 for treating acute myeloid leukemia (AML) at the 67th ASH Annual Meeting. The data reveals promising preliminary antitumor activity and an acceptable safety profile for densified dosing regimens. Out of 54 patients, eight responded to the treatment, including significant reductions in bone marrow blasts for several patients. The findings support further exploration of MP0533's potential across various AML treatment settings.
Read more →MOLN▲ +7.5%on this news
Molecular Biosensors Market Analysis Report 2025: Rising Demand for Rapid, Accurate Diagnostics and Growing Adoption of Point-of-Care Testing Solutions - Global Trends and Opportunities 2020-2030F
The Global Molecular Biosensors Market is set to grow from USD 19.09 billion in 2024 to USD 28.50 billion by 2030, driven by increasing demand for rapid, accurate diagnostic tools. Key factors include the burden of chronic and infectious diseases, underscoring the need for effective diagnostics. However, high initial costs for advanced technologies pose challenges, particularly for smaller players in the market. Innovations such as AI integration are enhancing diagnostic precision, fostering further growth and adoption of biosensor technologies.
Read more →MOLNMolecular Diagnostics Collaboration and Licensing Agreements Trends Analysis Report 2025 with Directory of 759 Deals Signed Since 2016 by Company A-Z, Therapy Focus and Technology Type
The report titled "Molecular Diagnostics Collaboration and Licensing Deals 2016-2025" has been released, detailing 759 molecular diagnostics agreements. It provides a thorough analysis of the trends in collaboration and licensing in the industry from 2016 to 2025. The report includes financial terms where available and insights into the most active companies and deal types, enhancing the understanding of molecular diagnostics dealmaking. This updated version features profiles of the top companies and includes various tables and figures to illustrate significant trends.
Read more →MOLNMolecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
Molecular Partners presented new data on MP0712, a Radio-DARPin targeting DLL3, at the TRP Summit Europe 2025. The data includes promising initial human imaging results showing targeted delivery to tumors with minimal exposure to healthy organs. The company is preparing for a Phase 1 trial in the US, pending FDA approval, expected to start by the end of 2025.
Read more →MOLNMolecular Cloning Market to Attain USD 8.89 Billion by 2034, Driven by Expanding Healthcare Applications and Innovation
The global molecular cloning market is forecasted to grow from USD 5.25 billion in 2024 to USD 8.89 billion by 2034, reflecting a compound annual growth rate of 5.4%. This growth is driven by expanding applications in healthcare, advancements in gene therapies, and increasing demand for personalized medicine. North America currently dominates the market, while Asia Pacific is anticipated to experience the fastest growth due to rising biopharmaceutical production. However, high costs and technical challenges remain significant hurdles for market participation.
Read more →MOLN▲ +12.4%on this news· ran to +29% by day 3
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
Molecular Partners announced it will present updated data from its Phase 1/2a trial of MP0533, a T cell engager for acute myeloid leukemia (AML), at the upcoming ASH Annual Meeting. The trial, which evaluates MP0533 in relapsed/refractory AML patients, has shown promising safety and preliminary efficacy results. The presentation is scheduled for December 7, 2025.
Read more →MOLN▲ +12.4%on this news· ran to +29% by day 3
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
Molecular Partners will present new preclinical data on its logic-gated CD3 Switch-DARPin T cell engager at the SITC 2025 meeting. The data indicate that the Switch-DARPin can selectively activate T cells against tumors expressing both mesothelin and EpCAM, leading to significant tumor regression without systemic toxicity. This approach may enhance the efficacy and safety of cancer treatments.
Read more →MOLN▲ +12.4%on this news· ran to +29% by day 3shared move
Molecular Diagnostics for Cancer Markets Forecasts 2025-2030: Accelerated Growth Driven by Trends Like Personalized Medicine, Pharmacogenomics, and Liquid Biopsy
The report on Molecular Diagnostics for Cancer projects significant growth in the sector from 2025 to 2030, driven by personalized medicine and advancements in diagnostic technology. It highlights the emergence of new markets and the reshaping of the industry through segments like companion diagnostics. Additionally, the report provides essential data for analysts and planners, supporting strategic facility planning and investment decisions. However, it notes challenges such as falling prices and potential regulatory hurdles.
Read more →MOLNMolecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
Molecular Partners reported its Q3 2025 financial results, highlighting progress in its clinical pipeline, including the upcoming Phase 1 trial for MP0712 targeting DLL3 in lung cancer. The company also noted promising results for MP0533 in AML and ongoing collaborations with Orano Med. Initial imaging data for MP0712 will be presented at an upcoming summit.
Read more →MOLNMolecular Spectroscopy Market to Reach USD 9.04 Billion by 2034, Driven by Expanding Healthcare Applications and Research Growth
The molecular spectroscopy market is projected to grow from USD 6.97 billion in 2024 to USD 9.04 billion by 2034, reflecting a 2.64% CAGR. This growth is primarily driven by increasing applications in diagnostics and personalized medicine, along with a rise in research and development activities. North America currently dominates the market, but the Asia Pacific region is anticipated to experience the fastest growth. While technological advancements highlight the potential for innovation within the sector, challenges such as high operational costs and regulatory barriers remain.
Read more →MOLN▼ -7.7%on this news
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
Molecular Partners reported positive progress in its clinical pipeline and financial results for H1 2025. The company is advancing its lead program MP0712 towards first-in-human trials and has shown promising results with MP0533 in acute myeloid leukemia. Additionally, the appointment of a new Chief Scientific Officer and a strategic review of operations were highlighted. Financial projections remain strong, extending funding into 2028.
Read more →MOLNMolecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
Molecular Partners has appointed Martin Steegmaier, Ph.D., as Chief Scientific Officer, effective October 1, 2025. Steegmaier, who has a strong background in oncology and drug development, is expected to lead the company's research initiatives and advance its DARPin therapeutic pipeline. His experience includes significant roles at major biotech firms, enhancing Molecular Partners' capabilities in cancer therapy.
Read more →MOLN▼ -8%on this news
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
Molecular Partners and Orano Med announced the preclinical data for their Radio-DARPin candidate MP0726, targeting mesothelin, at the SNMMI 2025 meeting. The data indicates high affinity binding and favorable biodistribution in MSLN-positive tumors. This candidate represents a promising advancement in targeted cancer therapies, particularly for ovarian cancer.
Read more →MOLN▲ +8%on this news
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape
The report on the molecular diagnostics for cancer market forecasts significant growth by 2025, driven by advancements in personalized medicine and liquid biopsies. It highlights the transformative role of cancer companion diagnostics and offers essential insights for stakeholders to capitalize on emerging trends. With detailed analytical data across multiple countries and regions, the report aims to guide decision-makers in strategic planning and investment within the evolving landscape of cancer diagnostics.
Read more →MOLN▲ +8%on this newsshared move
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
Molecular Partners announced positive results from a Phase 1/2a trial of MP0533 in relapsed/refractory acute myeloid leukemia (AML) at the EHA Congress. In cohort 8, over 30% of evaluable patients achieved clinical responses, including a complete response. The trial utilized an accelerated dosing regimen, leading to longer exposure and improved outcomes. Cohort 9 is currently underway, with initial data expected in H2 2025.
Read more →MOLNMolecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
Molecular Partners has announced a strategic review aimed at increasing operational efficiency, resulting in a planned workforce reduction of up to 40 positions. This move is expected to extend the company's cash runway into 2028, allowing for continued development of its clinical assets, particularly MP0533 and MP0712. The company will support affected employees during this transition.
Read more →MOLNMolecular Diagnostics Collaboration and Licensing Agreements Analysis Report 2025 with Directory of 759 Deals Signed Since 2016 - Upfront, Milestone, Royalties Financial Terms
The report titled 'Molecular Diagnostics Collaboration and Licensing Deals 2016-2025' provides a comprehensive analysis of molecular diagnostics agreements since 2016. It details 759 deals, including financial terms and contract documents where available. Key insights include trends in dealmaking, benchmarking analysis, and critical information on deal structures and responsibilities. This report serves as a crucial resource for stakeholders in the biopharma industry looking to understand the landscape of molecular diagnostics collaborations.
Read more →MOLNMolecular Partners to Present at Upcoming Investor Conferences
Molecular Partners AG announced its participation in two upcoming investor conferences, the H.C. Wainwright 3rd Annual BioConnect Investor Conference and TD Cowen’s 6th Annual Oncology Innovation Summit. Both events will be webcasted and accessible via the company's website. This engagement reflects the company's commitment to transparency and investor relations.
Read more →MOLNMolecular Partners Reports Financial Results and Highlights from Q1 2025
Molecular Partners reported its financial results and significant milestones for the first quarter of 2025, indicating strong progression in various clinical programs. The company is set to file an IND and release initial clinical data for its targeted Radio-DARPin therapy MP0712 later this year. Additionally, promising data from the Phase 1/2a trial of MP0533 in acute myeloid leukemia demonstrate improved response rates. A substantial cash position provides stability for the company's operations well into 2027, and strategic partnerships are expanding.
Read more →MOLNMolecular Oncology Diagnostics Market Report 2025 with Regional Growth Forecasts to 2033 - Increasing Growth Opportunities in Emerging Economies
The molecular oncology diagnostics market is projected to grow significantly from $2.41 billion in 2024 to $6.19 billion by 2033, driven by technological advancements and increased cancer prevalence. Key technologies influencing this growth include next-generation sequencing and liquid biopsy. However, challenges such as high costs and a shortage of qualified professionals in the field may hinder the market's expansion. Strategic collaborations and innovations are necessary to maximize the potential of molecular diagnostics in cancer treatment.
Read more →MOLNMolecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025
Molecular Partners AG presented optimistic preclinical data at the AACR Annual Meeting 2025, focusing on their Radio-DARPin programs developed in collaboration with Orano Med. The data includes positive findings for MP0712, which targets DLL3 and is set to advance into clinical development in 2025. Additionally, new preclinical results were shared regarding a targeted Radio-DARPin against mesothelin and further advancements in their T cell engager program suggest increased tumor specificity. These developments showcase the innovative potential and progress of Molecular Partners' DARPin technology in oncology.
Read more →MOLN▼ -8.7%on this news
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting
Molecular Partners AG has successfully concluded its Annual General Meeting with shareholders approving all proposals from the Board of Directors. Key approvals include the review of financial statements and the compensation report, alongside the re-election of Board members for another year. However, shareholders acknowledged a significant net loss of CHF 50,643,414 for 2024, which has resulted in a higher carried forward loss. The company continues to focus on its development of DARPin therapeutics amid these financial challenges.
Read more →MOLNMolecular Diagnostic for Infectious Diseases Market Size to Reach $17.61 Billion by 2030, Driven by Technological Advancements and Rising Global Disease Burden - The Insight Partners
The molecular diagnostics for infectious diseases market is projected to grow from $6.83 billion in 2022 to $17.61 billion by 2030, reflecting a compound annual growth rate (CAGR) of 12.5%. This growth is attributed to technological advancements in testing methods and a rising global burden of infectious diseases. Notable contributions have been made by key players such as F. Hoffmann-La Roche and Abbott, with innovations in PCR and other diagnostic techniques. Increased demand for rapid and accurate testing solutions, especially following the COVID-19 pandemic, is expected to further stimulate this market's expansion.
Read more →MOLNMolecular Partners to hold three poster presentations at AACR 2025
Molecular Partners AG has announced three upcoming poster presentations at the American Association for Cancer Research Annual Meeting 2025. The presentations will highlight new data on its innovative Radio-DARPin therapies targeting DLL3 and mesothelin, as well as advancements in CD3 Switch-DARPin technology for solid tumors. Notably, the company is preparing to enter first-in-human studies for MP0712 aimed at treating small cell lung cancer. The meeting will take place in Chicago, IL from April 25-30, 2025.
Read more →MOLNMolecular Partners Publishes Invitation to Annual General Meeting 2025
Molecular Partners AG has announced its Annual General Meeting scheduled for April 16, 2025, in Schlieren, Switzerland. Key agenda items include interim management statements and the release of half-year results for 2025. The company remains focused on developing DARPin therapeutics as part of its clinical programs. Additional details regarding future clinical trials and the company's strategic direction were also highlighted.
Read more →MOLNMolecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
Molecular Partners (MOLN) reported positive developments in its Q4 2024 highlights, showcasing advancements in its Radio-DARPin programs. The company anticipates entering first-in-human studies for MP0712 in 2025 and has expanded its collaboration with Orano Med to include ten targeted radiotherapy programs. Financially, Molecular Partners is well-positioned, with CHF 149 million in cash supporting operations through 2027. Additionally, the clinical trial data for MP0533 show promising results, potentially enhancing treatment for acute myeloid leukemia.
Read more →MOLNMolecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call
Molecular Partners AG has announced its participation in several upcoming investor conferences, including the TD Cowen and Leerink healthcare conferences. The company will also host a conference call to discuss its financial results for the year 2024 on March 7, following the publication of its Annual Report on March 6. Key executives will be presenting at these events, emphasizing the company's commitment to engaging with investors and promoting its DARPin therapeutics focused on oncology.
Read more →MOLNMolecular Cytogenetics Market Size to Expand USD 6.9 Bn by 2034
The global molecular cytogenetics market is set to see substantial growth, projected to reach USD 6.23 billion by 2033, up from USD 2.51 billion in 2024. Key factors driving this expansion include an uptick in genetic disorders, increased adoption of fluorescence in situ hybridization (FISH), and a heightened focus on personalized medicine. Notably, North America leads in market share due to advanced healthcare infrastructure and growing awareness. In contrast, the Asia-Pacific region is expected to experience the fastest growth driven by government initiatives and increasing genomic research efforts.
Read more →MOLNMolecular Cytogenetics Market Outlook 2025-2030: Rising Adoption of Advanced Genomic Technologies Fuels Growth of the $6.92 Billion Molecular Cytogenetics Market by 2034
The global molecular cytogenetics market is forecasted to expand significantly, from USD 2.28 billion in 2023 to USD 6.92 billion by 2034, with a compound annual growth rate of 10.63%. Growth is attributed to rising cancer and genetic disorder rates, advancements in personalized medicine, and ongoing research and development activities. Notable collaborations, such as that between Oxford Gene Technology and Applied Spectral Imaging, are enhancing cytogenetic imaging capabilities. Key segments driving the market include consumables and oncology applications, with North America expected to hold the largest market share.
Read more →MOLN▲ +8.3%on this news
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
Molecular Partners and Orano Med have expanded their collaboration to develop an additional six targeted alpha therapeutic candidates. This agreement builds on their initial partnership from January 2024, bringing the total number of programs to ten. The most advanced candidate, MP0712, is scheduled to enter clinical trials in 2025. The collaboration enables the utilization of Molecular Partners' unique Radio-DARPin platform alongside Orano Med's 212Pb supply, aiming to innovate in the field of targeted alpha therapies for cancer treatment.
Read more →MOLN▲ +8.3%on this news
Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference
Molecular Partners provided an update on its clinical expansion plans during the 43rd Annual J.P. Morgan Healthcare Conference. The company announced that MP0712, a Radio-DARPin targeting DLL3, is set to enter a first-in-human study in 2025, with additional targets in development under their partnership with Orano Med. The updates also included positive preliminary results from the MP0533 candidate in relapsed/refractory acute myeloid leukemia, demonstrating improved patient responses. The company expects further data updates throughout 2025.
Read more →MOLNMolecular Diagnostics for Cancer Market Report 2025: Cancer Companion Diagnostics is Reshaping the Industry
A new report by ResearchAndMarkets.com highlights the resurgence and projected growth of the molecular diagnostics market for cancer. It emphasizes the importance of cancer companion diagnostics which are reshaping the industry landscape. The report provides in-depth data across multiple countries, forecasts growth, and outlines various influential trends in the sector. Notable advancements in personalized medicine and technology-driven diagnostic tests are expected to drive market expansion.
Read more →MOLNMolecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
Molecular Partners AG will present its recent developments and future outlook at two significant investor conferences in January 2025. The first is the Baader Helvea Swiss Equities Conference scheduled for January 8-10 in Bad Ragaz, Switzerland, and the second is the 43rd Annual JP Morgan Healthcare Conference from January 13-16 in San Francisco, CA. The presentations will be made by key executives, including COO Alexander Zürcher and CEO Patrick Amstutz, and will provide important insights into the company's progress and plans in the field of DARPin therapeutics.
Read more →MOLNMolecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
Molecular Partners AG has presented new clinical and preclinical data at ASH 2024 for its investigational drugs MP0533 and MP0621. The ongoing phase 1/2a study of MP0533 shows an acceptable safety profile and initial signs of efficacy despite sub-optimal drug exposure. The company is amending the study protocol to optimize dosing and enhance therapeutic potential in patients with acute myeloid leukemia (AML). Concurrently, MP0621 has shown promise in preclinical evaluations for its targeted action in hematopoietic stem cell transplantation, though its applicability for AML patients is inconclusive based on current data.
Read more →MOLNMolecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
Molecular Partners AG has presented encouraging preclinical proof-of-concept data for its CD3 Switch-DARPin T cell engager platform, which activates T cells in the presence of tumor targets. Additionally, the company showcased comprehensive clinical biomarker analyses from its Phase 1 trial of MP0317, indicating effective CD40 activation within the tumor microenvironment. These developments will be presented at the upcoming SITC 2024 conference, highlighting advancements in their cancer treatment strategies.
Read more →MOLN▼ -5.1%on this newsshared move
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
Molecular Partners AG announced upcoming poster presentations at the 65th ASH Annual Meeting, showcasing data from their MP0533 and MP0621 studies. The MP0533 program focuses on treating relapsed/refractory acute myeloid leukemia and demonstrates an acceptable safety profile alongside initial antitumor activity. The MP0621 candidate is designed for hematopoietic stem cell transplantation, offering a new approach with reduced toxicity. Both posters will be presented on December 8 and 9, 2024, in San Diego, highlighting the company's advancements in DARPin therapeutics.
Read more →MOLN▼ -5.1%on this newsshared move
Molecular Health Technologies Named Supplement Manufacturing Company of the Year by Food Business Review
Molecular Health Technologies (MHT) has been named 'Supplement Manufacturing Company of the Year' by Food Business Review for its contributions to the supplement industry. The company focuses on developing high-quality, clinically-studied ingredients and has achieved significant biopharmaceutical innovation with new products like Sebrium DCD® and BerberiSol™, which are designed to improve absorption and meet modern consumer needs. MHT also aims to revolutionize supplement delivery methods, ensuring that they align with today's fast-paced lifestyle.
Read more →MOLN▼ -12.8%on this newsshared move
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
Molecular Partners has provided updates on its business and clinical developments in the third quarter of 2024. The company is preparing to initiate clinical trials for the Radio-DARPin candidate MP0712 in 2025, backed by encouraging preclinical data. They have also reinforced a strategic partnership with Orano Med to co-develop multiple RDT candidates, enhancing their pipeline. Additionally, the company reported sufficient funding to sustain operations through 2027, with positive clinical developments on other candidates, including MP0533 and MP0621, slated for upcoming presentations.
Read more →MOLN▲ +7.8%on this news
Molecular Partners Announces Pricing of $20 Million Underwritten Offering ZURICH-SCHLIEREN, Switzerland, and
Molecular Partners AG has announced the pricing of a $20 million underwritten offering, set to close on October 29, 2024. Approximately 3,642,988 American Depositary Shares (ADSs) will be sold at $5.49 per ADS, with participation from new and existing investors. The proceeds from the offering will be directed toward the development of the company's radiopharmaceutical pipeline and working capital. This offering is being conducted under an effective F-3 shelf registration statement filed with the SEC.
Read more →MOLNMolecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
Molecular Partners and Orano Med announced additional positive preclinical data for their DLL3-targeting Radio-DARPin therapeutic candidate MP0712 at the EANM Congress. The data showed dose-dependent efficacy and a favorable safety profile with strong tumor uptake and low kidney exposure. They are preparing to start first-in-human studies in 2025, with initial clinical data expected the same year. This candidate may become the first DLL3-targeting 212Pb agent in development, demonstrating significant promise in treating small cell lung cancer.
Read more →MOLNMolecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
Molecular Partners and Orano Med have revised their co-development agreement for 212Pb-based Radio-DARPin therapeutics, increasing the number of programs to four. Each company will hold commercialization rights to two of the programs, including Molecular Partners' MP0712 targeting DLL3. The revised agreement anticipates the initiation of first-in-human studies for MP0712 in 2025, pending regulatory clearance. Molecular Partners maintains its funding guidance and estimates approximately CHF 140 million in cash reserves as of September 30, 2024.
Read more →MOLN▲ +9.6%on this news
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
Molecular Partners AG has announced upcoming poster presentations for the 2024 SITC Annual Meeting, showcasing preclinical proof-of-concept data for their CD3 Switch-DARPin platform. Additionally, the company will present findings from a Phase 1 study of MP0317, focusing on its impact on solid tumors. The presentations highlight advancements in T cell engagers with enhanced functions and provide insights into tumor microenvironment modulation. This event marks an important opportunity for Molecular Partners to share its cutting-edge research with the scientific community.
Read more →MOLN▲ +8.1%on this news
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
Molecular Partners AG announced it will present its lead 212Pb-labeled Radio-DARPin therapeutic, MP0712, at the European Association of Nuclear Medicine (EANM) Congress in October 2024. The therapy targets DLL3 for treating small cell lung cancer and has demonstrated strong tumor growth inhibition along with a favorable safety profile in preclinical studies. This presentation will showcase preclinical results supporting MP0712 as a promising candidate for clinical development.
Read more →MOLNMolecular Partners Reports H1 2024 Corporate Highlights and Financials
Molecular Partners AG has reported significant advancements in its development pipeline during the first half of 2024, including the nomination of its first Radio-DARPin Therapy candidate, MP0712, aimed at treating DLL3-expressing tumors. The company has entered a strategic collaboration with Orano Med to co-develop 212Pb-based therapies, and progress continues on its MP0533 program for acute myeloid leukemia. Positive data from various studies underscore the potential of their therapies and highlight a solid financial position that supports ongoing projects. Further clinical updates are anticipated in 2024 and beyond.
Read more →MOLNMolecular Cytogenetics Market Size Envisaged To Reach USD 8.8 Billion by 2034, Projected 11.0% CAGR Growth: Prophecy Market Insights
The molecular cytogenetics market is expected to experience substantial growth, with a projected increase from USD 3.4 Billion in 2024 to USD 8.8 Billion by 2034, reflecting a CAGR of 11.0%. Factors fueling this growth include advancements in technology, a rising number of oncology cases, and heightened public awareness. However, the market faces challenges from high costs and a lack of understanding regarding new diagnostic methods. North America is anticipated to lead the market due to its advanced healthcare infrastructure and increased research funding.
Read more →MOLN▲ +7.7%on this news· ran to +42% by day 3
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
Molecular Partners AG will present at the TD Cowen Radiopharmaceutical Innovation Summit on June 17, 2024, where Michael Stumpp, the co-founder, will participate in a fireside chat. This event highlights the company's ongoing efforts in developing DARPin therapeutics, particularly for oncology. The presentation will be available via live webcast and archived on their website for future reference. Molecular Partners is positioned as a leader in addressing unique medical challenges through its proprietary programs and partnerships.
Read more →MOLN▲ +13.8%on this news· ran to +85% by day 3shared move
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
Molecular Partners announced positive preclinical data for MP0621, a multivalent Switch-DARPin candidate targeting cKit, CD16a, and CD47. This data validates its potential to enhance hematopoietic stem cell transplantation outcomes for AML patients while minimizing toxicity. MP0621 is undergoing IND-enabling studies, with Phase 1 trials expected in 2025. The encouraging results are set to be presented at the EHA 2024 Congress in Madrid, emphasizing the transformative potential of this new therapeutic approach.
Read more →MOLN▲ +13.4%on this news· ran to +54% by day 3shared move
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
Molecular Partners and Orano Med presented promising preclinical data for MP0712, a DLL3-targeting Radio-DARPin therapy, at the SNMMI 2024 Annual Meeting. The data indicate strong tumor uptake and a favorable safety profile, paving the way for an anticipated first-in-human study expected in 2025. MP0712 represents a significant advancement in targeted therapy for small-cell lung cancer and other neuroendocrine tumors, with further development planned to expand the RDT platform's target portfolio.
Read more →MOLNMolecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
Molecular Partners AG presented positive final data from its Phase 1 trial of MP0317, a DARPin therapeutic targeting advanced solid tumors, at the ASCO Annual Meeting 2024. The trial demonstrated a favorable safety profile and the drug's potential to modulate the tumor microenvironment effectively. Evidence included one unconfirmed partial response and stable disease in 14 patients. Despite these encouraging results, there was a report of dose-limiting toxicity in one patient. The company plans to seek collaborations for further clinical evaluations.
Read more →MOLNMolecular Diagnostics Collaboration and Licensing Deals Analysis Report 2024 with Directory of 740 Agreements Signed Since 2019
ResearchAndMarkets.com has released a new report titled "Molecular Diagnostics Collaboration and Licensing Deals 2016-2024," offering comprehensive insights into 740 agreements made since 2016. The report outlines significant trends in molecular diagnostics deals, emphasizing terms such as financials, collaboration specifics, and the responsibilities of partner companies. Additionally, it includes a directory of deals organized by various factors and aims to streamline the due diligence process for stakeholders in the biopharma industry. This updated resource will assist companies in analyzing past agreements to guide future collaborations.
Read more →MOLNMolecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
Molecular Partners announced the publication of preclinical data on its tetra-specific T cell engager, MP0533, which reveals its mechanism of action against acute myeloid leukemia (AML). The research indicates that MP0533 selectively activates T cells and can induce tumor regression without harming healthy cells. This publication builds on previous findings and supports MP0533's clinical development as a potential treatment for AML, currently being evaluated in an ongoing Phase 1/2a trial. The company aims to provide further updates on this study in the first half of 2024.
Read more →MOLNMolecular Partners Announces All Board Proposals Approved at the Annual General Meeting
Molecular Partners AG announced that all board proposals presented at its Annual General Meeting were overwhelmingly approved by shareholders. Key approvals included the financial statements for 2023 and amendments to the articles of incorporation. The shareholders also confirmed the re-election of all board members and the compensation plans for the board and management. Additionally, KPMG AG Zurich was re-elected as statutory auditors for the financial year 2024.
Read more →MOLN▼ -7.1%on this news
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
Molecular Templates, Inc. has announced a new private placement offering, generating $9.5 million in gross proceeds through an amended securities purchase agreement. This financing, led by existing investors, will involve the issuance of common stock and warrants. The funds are designated for ongoing clinical studies and general corporate purposes. However, the transaction is subject to standard closing conditions, and the securities sold will not be publicly offered. Additionally, the company faces various risks related to its financial stability and operational future.
Read more →MOLNMolecular Partners Publishes Invitation to Annual General Meeting 2024
Molecular Partners AG has published the invitation for its Annual General Meeting scheduled for April 17, 2024. This meeting marks an important event for shareholders and will take place at JED Events in Schlieren, Switzerland. The company also provided a timeline of significant upcoming events, including interim management statements and half-year results, emphasizing its continued operational transparency and engagement with investors. As a clinical-stage biotech focused on DARPin therapeutics, Molecular Partners aims to address complex medical challenges.
Read more →MOLNMolecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
Molecular Partners provided key updates in its Q4 2023 report, highlighting encouraging initial data from the Phase 1/2a trial of MP0533 for AML, showcasing an acceptable safety profile and early anti-tumor activity. The company also introduced their innovative Switch-DARPin platform, with plans for further clinical and preclinical developments slated for 2024. Additionally, Molecular Partners reported a solid financial position, with sufficient funds to support operations into 2026. The company is preparing to expand clinical trials and introduce new therapeutic strategies.
Read more →MOLNMolecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
Molecular Partners AG announced that it will release its fourth quarter and full year financial results for 2023 on March 14, 2024. Following this, a conference call will be held on March 15 to discuss these results. Additionally, CEO Patrick Amstutz will present at the 44th Annual Cowen Health Care Conference and participate in the Leerink Global Biopharma Conference. The full year results presentation will be available via webcast and will include a replay for 90 days.
Read more →MOLNMolecular Partners Announces Dismissal of Class Action Lawsuit
Molecular Partners AG has announced that a class action lawsuit against the company, its directors, and certain executive officers has been dismissed by the court. The original complaint, which alleged violations of federal securities laws over misrepresentations related to their product candidate MP0310, was closed following the plaintiff's filing of a dismissal with prejudice. Legal representation for the company was handled by Cooley LLP. This development allows Molecular Partners to concentrate on its drug development efforts without the distraction of litigation.
Read more →MOLNMolecular Cloning Kits Market projected to reach USD 1,250.25 Million by 2030, growing at a CAGR of 16.4% during the forecast period of 2023-2030 - claims by MarketDigits in its recent study
The Molecular Cloning Kits Market is forecasted to reach USD 1,250.25 million by 2030, growing at a CAGR of 16.4% from 2023 to 2030. This growth is propelled by advancements in gene editing technologies and an increasing emphasis on personalized medicine. North America is identified as the leading region in this market, benefiting from a robust research infrastructure and established industries. However, the market faces challenges, including stringent regulatory requirements and the complexities of cloning procedures.
Read more →MOLN▲ +11.8%on this news
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
Molecular Partners AG provided key updates at the 42nd Annual J.P. Morgan Healthcare Conference. The company highlighted promising data from its MP0533 clinical trial for r/r AML and plans for the Radio-DARPin Therapy pipeline. Additionally, they introduced a new Switch-DARPin program aimed at improving hematopoietic stem cell transplantation outcomes. Despite recent advances, Molecular Partners faces challenges, such as the return of rights for previously abandoned products.
Read more →MOLNMolecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
Molecular Partners AG and Orano Med have entered a co-development agreement focused on Radio-DARPin therapeutics for oncology targets, particularly DLL3. This initiative will utilize Orano Med's 212Pb radioisotope to selectively target and kill cancer cells. The partnership aims to expedite clinical development, with initial human studies expected to commence in 2025. Both companies are committed to sharing the costs involved in preclinical and clinical development, indicating strong collaboration potential in advancing these new therapies.
Read more →MOLNMolecular Cytogenetics Market Analysis Report 2023-2030, Featuring Profiles of Bioview, Danaher, Metasystems, Agilent Technologies, Bio-Rad Laboratories & Quest Diagnostics
The Molecular Cytogenetics Market is projected to grow significantly, reaching USD 4.46 billion by 2030 with a compound annual growth rate (CAGR) of 10.6%. Key drivers include rising applications in oncology and personalized medicine, technological advancements, and increasing genetic disorder incidences. The impact of the COVID-19 pandemic has also highlighted the relevance of the field, particularly in public health genomics. While growth prospects are strong, challenges such as high testing costs and reimbursement issues may hinder progress.
Read more →MOLN▲ +7.4%on this news
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
Molecular Partners AG will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference and other events in Switzerland. CEO Patrick Amstutz and COO Alexander Zürcher are slated to speak at specific times during these conferences. The company is focused on advancing its innovative DARPin therapeutics for oncology and infectious diseases, currently in various stages of development. Webcast presentations will be made available on their website post-event.
Read more →MOLN▼ -7.5%on this newsshared move
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
Molecular Partners presented initial positive data from their ongoing Phase 1/2a trial for MP0533, a novel T cell engager for patients with relapsed/refractory AML and MDS. The trial has shown encouraging antitumor activity, including a complete response at lower-than-expected doses and an acceptable safety profile with no dose-limiting toxicities reported. Currently, patients are being enrolled in the fifth cohort of seven planned dose-escalation cohorts as the trial continues. The results were showcased at the American Society of Hematology Annual Meeting.
Read more →MOLNMolecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
Molecular Partners AG is set to showcase its DARPin oncology innovations at the 15th Annual Protein & Antibody Engineering Summit in Lisbon. The presentation will highlight various mechanisms of action leveraging DARPin platforms for conditional immune activation against tumors, thereby minimizing damage to healthy cells. Promising data from their MP0317 trial and anticipated results for MP0533 will also be shared, underlining the company's focus on cancer therapeutics. Additionally, advancements in their Radio-DARPin Therapy platform will be discussed, emphasizing their ongoing commitment to innovative cancer treatment solutions.
Read more →MOLN▲ +10.5%on this news
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
Molecular Partners AG presented updated data from their Phase 1 trial of MP0317, a CD40 agonist for advanced solid tumors, at the 2023 SITC Annual Meeting. The findings indicate that MP0317 effectively activates immune cells localized within the tumor microenvironment while maintaining a favorable safety profile across all doses. Patient recruitment is concluded, with preliminary data showing some encouraging responses and the potential for further evaluations in combination studies. Final study results are anticipated to be released in H1 2024.
Read more →MOLN▲ +14.5%on this news· ran to +27% by day 1shared move
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
Molecular Partners AG announced preliminary data on its Phase 1/2a trial of MP0533, a tetra-specific T cell engager, for treating relapsed/refractory AML and AML/MDS. The data, presented ahead of the ASH Annual Meeting, show an acceptable safety profile with no dose-limiting toxicities and evidence of antitumor activity in one patient from the study. Results will be further explored in upcoming presentations, with additional cohorts planned as the company seeks to validate this innovative approach to blood cancer treatment.
Read more →MOLNMolecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
Molecular Partners AG is set to participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit on November 3, 2023. CEO Patrick Amstutz and acting CMO Dr. Philippe Legenne will represent the company in a fireside chat. This participation showcases the company's commitment to advancing its DARPin therapeutics, which are in various stages of development across multiple therapeutic areas.
Read more →MOLN▲ +5.3%on this newsshared move
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
Molecular Partners AG reported significant developments in their third quarter 2023 management statement, highlighting the completion of recruitment for their MP0317 Phase 1 trial and ongoing progress in the MP0533 trial for relapsed/refractory AML. The company announced upcoming data presentations at major oncology conferences, including the SITC and ASH meetings. Their Radio-DARPin Therapy platform is showing promise, with recent advancements shared at the EANM meeting. Financially, the company maintains a robust cash position, ensuring funding through 2026.
Read more →MOLNMolecular Diagnostic for Infectious Diseases Market Size Worth $17.61 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
The global market for molecular diagnostics in infectious diseases is set to grow significantly, reaching an estimated $17.61 billion by 2030, up from $6.88 billion in 2022, with a compound annual growth rate (CAGR) of 12.5%. This growth is driven by rising incidences of infectious diseases and the need for accurate and timely diagnostics. Key players in the industry are focusing on product development and market expansion, leveraging new technologies and addressing the demands of both point-of-care and laboratory testing sectors. The report details various applications and geographical market insights, signaling a dynamic future for the sector.
Read more →MOLN▼ -5.4%on this news
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
Molecular Partners AG has unveiled new preclinical data from its Radio-DARPin Therapy (RDT) platform at the EANM 2023 Annual Meeting. The data indicate that DARPins can be engineered to significantly improve tumor uptake while minimizing kidney accumulation, thereby enhancing safety profiles. The findings support the potential for a broader application of RDT across various tumor targets and indicate a favorable efficacy-to-safety ratio. These advancements may lead to new therapeutic options in radioligand therapy.
Read more →MOLNMolecular Partners Reports H1 2023 Corporate Highlights and Financials
Molecular Partners AG reported significant corporate highlights and financials for H1 2023, including the initiation of a Phase 1/2a trial for MP0533, a tetraspecific T cell engager aimed at treating relapsed/refractory AML. The company also shared promising data on its Phase 1 trial of MP0317, a CD40 agonist designed for advanced solid tumors. Overall, Molecular Partners appears well-positioned financially with a cash reserve of CHF 218 million, allowing continued development of its innovative therapies. They expect initial clinical data from MP0533 by Q4 2023, and further information regarding MP0317 in H2 2023.
Read more →MOLNMolecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
Molecular Partners AG has announced an upcoming presentation on its Radio DARPin Therapy (RDT) Platform during the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. This platform aims to improve the targeting efficiency and safety of radioactive payload delivery to solid tumors, with preclinical data supporting its effectiveness. RDT technology is designed to selectively deliver radionuclides to tumors while minimizing damage to healthy tissues, particularly the kidneys. The first target for this proprietary technology is the tumor-associated protein DLL3.
Read more →MOLNMolecular Diagnostics Market (Disease Area, Technology) – Reach $36.17 Billion by 2028 at 12.1% CAGR with Oncology Segment Driving Growth During 2022-2028 | The Insight Partners
A recent report indicates that the global molecular diagnostics market is projected to experience substantial growth, estimated to expand from $16.26 billion in 2021 to $36.18 billion by 2028, with a compound annual growth rate of 12.1%. Key segments include oncology and various technologies such as PCR and DNA sequencing. The report highlights market opportunities particularly in the Asia Pacific region due to the established healthcare systems and active market participation. However, certain limitations associated with molecular testing may pose challenges to this growth.
Read more →MOLNMolecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
Molecular Partners AG announced positive results from the ongoing Phase 1 study of MP0317, a CD40 agonist targeting the tumor microenvironment. The data reveal successful tumor-localized CD40 activation and a favorable safety profile across multiple dosing regimens. Notably, clinical evaluations showed promising immune activation, supporting the drug's potential for combination studies in treating advanced solid tumors. The presentation of these findings is scheduled for the 2023 ASCO Annual Meeting.
Read more →MOLNMolecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
Molecular Partners AG, a clinical-stage biotech firm based in Switzerland, announced its participation in the 2023 RBC Capital Markets Global Healthcare Conference. CEO Patrick Amstutz will speak at the event, scheduled for May 16-17, 2023. The company is notable for developing DARPin therapeutics, designed to tackle issues that current treatment methods struggle with. Additionally, Molecular Partners has formed collaborations with major pharmaceutical companies to enhance the development of its therapeutics across various areas.
Read more →MOLNMolecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR
Molecular Partners AG announced that it will present new preclinical data supporting its Radio DARPin Therapy Platform at the American Association for Cancer Research Annual Meeting. This data highlights the potential of DARPins to penetrate tumors effectively while reducing kidney accumulation. The presentation will take place on April 18, 2023, with insights from Senior VP of Research, Dr. Daniel Steiner. The research aims to overcome historical challenges faced by traditional protein-based delivery vectors.
Read more →MOLNMolecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
Molecular Partners AG announced that shareholders approved all board proposals during the Annual General Meeting, which occurred on April 4, 2023. The approvals included the review of financial statements for 2022, and a substantial reduction in the company's previous loss carried forward. Additionally, all board members were re-elected, ensuring continuity in leadership. The meeting also confirmed the appointment of KPMG AG Zurich as the statutory auditors for the financial year 2023.
Read more →MOLN▲ +9%on this news
Molecular Partners Publishes Invitation to Annual General Meeting 2023
Molecular Partners AG has published the invitation for its Annual General Meeting scheduled for April 4, 2023. The meeting will take place in Schlieren, Switzerland, and will cover various agenda items related to the company's operations and strategies. The firm is actively developing DARPin therapeutics and has a pipeline of compounds in different stages of development targeted at oncology and infectious diseases. Additionally, the company has announced upcoming financial reporting dates for interim management statements and half-year results.
Read more →MOLN▼ -5.3%on this newsshared move
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022
Molecular Partners announced its Q4 2022 corporate highlights, focusing on advancements in its drug pipeline and robust financial health. The company initiated a Phase 1 trial for MP0533, targeting acute myeloid leukemia, and received positive interim data on other candidates. While financial standing remains strong, marked by CHF 249.1 million in cash reserves, the withdrawal of the EUA for ensovibep due to efficacy concerns poses challenges. Leadership changes, including the departure of CFO Andreas Emmenegger, add to the transitional dynamics of the company.
Read more →MOLNMolecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference
Molecular Partners AG will issue a press release summarizing its fourth quarter and full year 2022 results, followed by an investor call. CEO Patrick Amstutz is scheduled to present at the 43rd Annual Cowen Health Care Conference on March 8, 2023. The financial results will be publicly available on March 9, 2023, and the conference call is set for March 10, 2023. The company is engaged in developing DARPin therapeutics and has ongoing partnerships in oncology and infectious disease.
Read more →MOLNMolecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform
Molecular Partners AG has presented new preclinical data from its Radio DARPin Therapy Platform, demonstrating significant advancements in delivering radioactivity to tumors while minimizing accumulation in the kidneys. This innovative approach could enhance both safety and efficacy in treating solid tumors. The data was showcased at the 12th International Symposium on Targeted Alpha Therapy and suggests a promising future for DARPin technology. Additionally, the company is moving forward with several programs, including a partnership with Novartis, targeting indications with high unmet medical needs.
Read more →MOLNMolecular Partners to Present at SVB Leerink Global Healthcare Conference
Molecular Partners AG announced that its CEO, Patrick Amstutz, will present at the upcoming SVB Leerink Global Healthcare Conference on February 15, 2023. The presentation will take place virtually and will be accessible through a webcast on the company's website. Molecular Partners is focused on developing DARPin therapeutics, which are designed to tackle challenges posed by existing treatment modalities across various therapeutic areas.
Read more →MOLNMolecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia
Molecular Partners AG has initiated a Phase 1 clinical study for its trispecific candidate MP0533, aimed at treating acute myeloid leukemia (AML). The treatment utilizes a novel mechanism that enhances selectivity for leukemic cells while preserving healthy cells. The study will evaluate the safety, tolerability, and efficacy of MP0533, enrolling 20-45 patients across Switzerland and the Netherlands, focusing on relapsed/refractory AML and higher-risk myelodysplastic syndromes. Preclinical data suggests promising efficacy in targeting both leukemic blast cells and leukemic stem cells.
Read more →MOLNMolecular You launches a new preventive solution shown to improve health outcomes over 100 days
Molecular You has launched a new preventive digital health solution that utilizes a novel blood test to analyze health risks across 26 areas. A pilot study with 122 participants demonstrated an average risk reduction of over 50% for conditions such as cardiovascular disease and diabetes after 100 days of following recommended interventions. The platform delivers personalized lifestyle change plans and employs a mobile app for user engagement, aiming to enhance preventive healthcare access in Canada. The service is currently available in Alberta, British Columbia, and Ontario.
Read more →MOLN▲ +10.9%on this newsshared move
Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference
Molecular Partners AG announced several key developments during the 41st Annual JPM Healthcare Conference, focusing on their DARPin therapeutics across infectious disease and oncology. The company disclosed DLL3 as the first target for its DARPin Radioligand Therapy platform and revealed a strong financial position with a cash runway into 2026. Notably, a partnership with Novartis aims to address global health threats, although the company also confirmed the withdrawal of the Emergency Use Authorization for ensovibep, which is not in clinical development. Milestones for 2023 include the initiation phases of various trials and scientific presentations on DARPin therapies.
Read more →MOLN▲ +6.2%on this news
Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief
Read more →MOLNMolecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML
New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagers Tri-specific T-cell engager resulted in AML cell-specific cytotoxicity with minimal off-tumor toxicity Phase I clinical trial evaluating safety and dose of MP05
Read more →MOLNMolecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors
First clinical observation of tumor localized CD40 activation provided by MP0317 No systemic or dose-limiting toxicities observed, a key parameter for CD40 agents Dose escalation remains ongoing with study recruitment anticipated to complete in 1H 2023 ZURICH-SCHLIEREN, Switze
Read more →MOLNMolecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the acceptance
Read more →MOLNMolecular Partners Announces Upcoming Participation in Investor and Scientific Conferences
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the team w
Read more →MOLNMolecular Partners Announces Planned Departure of Chief Financial Officer
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin t
Read more →MOLNMolecular Partners AG Investors: Last Days to Actively Participate in the Class Action Lawsuit; September 12, 2022 Deadline; Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Molecular Partners AG (“Molecular Partners” or “the Company”) (NASDAQ: MOLN) investors that a class action has b
Read more →MOLNMOLECULAR PARTNERS AG (NASDAQ: MOLN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Molecular Partners AG (NASDAQ: MOLN)
Did you lose money on investments in Molecular Partners? If so, please visit Molecular Partners AG Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Bernstein
Read more →MOLN▲ +10.2%on this newsshared move
Molecular Partners Reports Corporate Highlights and H1 2022 Financials
Molecular Partners Reports Corporate Highlights and H1 2022 Financials Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022 Initiation of Phase 1 study for MP0533 expected by year end Continued progression of propri
Read more →MOLNMolecular Partners AG Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 23, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Molecular Partners AG (“Molecular Partners” or “the Company”) (NASDAQ: MOLN) investors that a class action has be
Read more →MOLNMolecular Partners Half Year 2022 News Release and Investor Call Details
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summ
Read more →MOLNMOLECULAR PARTNERS CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Molecular Partners in the United States District Court for the Southern District of New York
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a federal securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or
Read more →MOLNMolecular Transport Medium Market is expected to progress at a CAGR of 1.2% over the forecast period (2022-2032) – Persistence Market Research
New York, July 25, 2022 (GLOBE NEWSWIRE) -- The molecular transport medium market was valued at around US$ 1.6 Bn in 2021 and is expected to progress at a CAGR of 1.2% over the forecast period (2022-2032). A molecular transport medium is useful for sample transport, as well as f
Read more →MOLNMolecular Partners AG Shareholder Update: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Molecular Partners AG (MOLN)
SAN DIEGO, July 22, 2022 (GLOBE NEWSWIRE) -- The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Molecular Partners AG (NASDAQ: MOLN) American Depository Shares
Read more →MOLNMolecular Partners Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARPin Antiviral for SARS-CoV-2
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the publication
Read more →MOLNMOLECULAR PARTNERS AG (NASDAQ: MOLN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Molecular Partners AG (NASDAQ: MOLN)
Did you lose money on investments in Molecular Partners? If so, please visit Molecular Partners AG Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Bernstein L
Read more →MOLNMolecular Partners Announces Participation in Scientific Conferences
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members o
Read more →MOLNMolecular Diagnostics Market to reach USD 33.5 Billion by 2030 | Exclusive MDC Research Report
Pune, May 26, 2022 (GLOBE NEWSWIRE) -- Molecular Diagnostics Market by Vendor Assessment, Technology Assessment, Partner & Customer Ecosystem, type/solution, service, organization size, end-use verticals, and Region – Global Molecular Diagnostics Market Forecast to 2030, publishe
Read more →MOLNMolecular Biology Enzymes, Kits, and Reagents Market Worth $41.10Bn, Globally, by 2028 at 17.8% CAGR Lead by Kits & Reagents Segment: The Insight Partners
New York, May 26, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Molecular Biology Enzymes, Kits, and Reagents Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product (Enzymes and Kits & Reagents), Application (Epigenetics, Se
Read more →MOLNMolecular Partners to Participate in Upcoming Healthcare Investor Conferences
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members of
Read more →MOLNMolecular Partners CEO, Patrick Amstutz, Elected President of the Swiss Biotech Association
BASEL, Switzerland and ZURICH-SCHLIEREN, Switzerland, May 03, 2022 (GLOBE NEWSWIRE) -- The Swiss Biotech Association and Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeu
Read more →MOLNMolecular Partners ADRs Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Molecular Partners AG
NEW YORK, April 29, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Molecular Partners AG ADRs ("Molecular Partners" or the "Company") (NASDAQ:MOLN). Molecular Partners shares suffered a dramatic drop aft
Read more →MOLN▼ -16.2%on this news· ran to -51% by day 3shared move
Molecular Partners to Regain Global Rights for MP0310 from Amgen
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin
Read more →MOLN▼ -16.2%on this news· ran to -51% by day 3shared move
Molecular Partners Provides Update on Ensovibep Following Novartis Quarterly Earnings Call
ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin th
Read more →MOLNMolecular Partners Announces Presentation of the EMPATHY Study of Ensovibep for the Treatment of COVID-19 at ECCMID 2022
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 23, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that late-brea
Read more →MOLNMolecular Partners to Present at Kempen Life Sciences Investor Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the compa
Read more →MOLNMolecular Partners Announces Publication of Preclinical Data from CD40 Therapeutic Candidate MP0317 in Cancer Immunology Research
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the publicatio
Read more →MOLNMolecular Partners Publishes Invitation to Annual General Meeting 2022
Molecular Partners Publishes Invitation to Annual General Meeting 2022 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built pr
Read more →MOLN▼ -9.2%on this newsshared move
Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021
Research & Development Highlights: In January of 2022, announced positive topline results from Phase 2 EMPATHY clinical trial of ensovibep for the treatment of non-hospitalized COVID-19 patients, resulting in the option exercise of the program by Novartis triggering the receipt
Read more →MOLN▲ +30.2%on this news· ran to +71% by day 3
Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19
Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19 Topline results from the randomized, placebo-controlled EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single
Read more →MOLNCustom Built Biology for Patients 1 Oncology Day 2021 Molecular P artners A G, S witzerland (SIX: MOLN)
Custom Built Biology for Patients 1 Oncology Day 2021 Molecular P artners A G, S witzerland (SIX: MOLN) This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact
Read more →MOLNMolecular Partners Reports Corporate Highlights and Key Financials for H1 2021
Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021 -- Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3 Research & D
Read more →Competitive Position
How MOLN ranks across every disease it competes inCompetitive Position is a premium feature
See how MOLN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial